Why Wall Street Is Becoming Even More Bullish About This Dividend King

Abbott Laboratories, a company with a rich history of raising dividends for 54 consecutive years, is attracting greater investor interest from Wall Street. This newfound bullish sentiment stems from the Medical Devices segment's rising earnings, which outpaced expectations, propelling overall sales growth. Abbott's Medical Devices segment grew by 8.4% on a comparable basis, generating nearly $6 billion in sales, with electrophysiology leading the charge.

Additionally, Abbott's diabetes business showed promising growth, especially with the launch of the Libre Duo continuous glucose monitor, which adds ketone monitoring capabilities. Strong financials, with $3.8 billion in operating cash flow in the first half of 2026, support these payouts, but the company faces challenges, as its Nutrition and Rapid and Molecular Diagnostics segments declined in earnings.

Despite its current valuation, which reflects optimism, Wall Street remains bullish on Abbott due to the promising growth outlook from its Medical Devices, Libre, and Exact Sciences acquisitions. This combination of growth factors and a strong dividend record makes Abbott an increasingly attractive income option for investors.